This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., May 14, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced the following scientific presentations:

Conference
20th European Congress on Obesity (ECO), Arena and Convention Centre Liverpool (UK)
 
Date / Time / Details
Poster Number: T5:P.106
Track Number: 5 
Session Date: Monday, May 13, 2013
Presentation Time: 1315 – 1445 hrs
 
Presentation Title
Does a History of Depression and/or Antidepressant Use Affect the Weight Loss Efficacy of Phentermine and Topiramate Extended-Release?
 
Authors
Patrick M. O'Neil, PhD a; Timothy Church, MD b; Barbara Troupin, MD, MBA c
 
Affiliations:
aMedical University of South Carolina, Charleston, SC
bPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA
cVIVUS, Inc., Mountain View, CA
 
Date / Time / Details
Presentation Date: Wednesday, May 15, 2013
Presentation Location: Hall 7
Session Time: 0945 – 1115 hrs
Presentation Time: 1000 – 1015 hrs
 
Presentation Title
Weight Loss and Improvements in Hypertension Status Associated With Phentermine and Topiramate Extended-Release Treatment in Obese and Overweight Adults
 
Authors
Nick Finer, MBBS, BSc, FRCP a Jens Jordan, MD b Roman V. Dvorak, MD, PhD c
 
Affiliations: 
aInstitute for Cardiovascular Science, University College London, UK
bInstitute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany
cVIVUS, Inc., Mountain View, CA

About Qsymia

Qsymia ® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs